Visit-to-Visit Glycemic Variability and Risks of Cardiovascular Events and All-Cause Mortality: The ALLHAT Study
Open accessThe DOI matches its Crossref record; 16 of the 16 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: The prognostic value of long-term glycemic variability is incompletely understood. We evaluated the influence of visit-to-visit variability (VVV) of fasting blood glucose (FBG) on incident cardiovascular disease (CVD) and mortality. RESEARCH DESIGN AND METHODS: We conducted a prospective cohort analysis including 4,982 participants in the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) who attended the baseline, 24-month, and 48-month visits. VVV of FBG was defined as the SD or variability independent of the mean (VIM) across FBG measurements obtained at the three visits. Participants free of CVD during the first 48 months of the study were followed for incident CVD (coronary heart disease [CHD], stroke, and heart failure [HF]) and all-cause mortality. RESULTS: Over a median follow-up of 5 years, there were 305 CVD events (189 CHD, 45 stroke, and 81 HF) and 154 deaths. The adjusted hazard ratio (HR) comparing participants in the highest versus lowest quartile of SD of FBG (≥26.4 vs. <5.5 mg/dL) was 1.43 (95% CI 0.93–2.19) for CVD and 2.22 (95% CI 1.22–4.04) for all-cause mortality. HR for VIM was 1.17 (95% CI 0.84–1.62) for CVD and 1.89 (95% CI 1.21–2.93) for all-cause mortality. Among individuals without diabetes, the highest quartile of SD of FBG (HR 2.67 [95% CI 0.14–6.25]) or VIM (HR 2.50 [95% CI 1.40–4.46]) conferred a higher risk of death. CONCLUSIONS: Greater VVV of FBG is associated with increased mortality risk. Our data highlight the importance of achieving normal and consistent glycemic levels for improving clinical outcomes.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A New Equation to Estimate Glomerular Filtration Rate
Levey, A. S., Stevens, L. A., Schmid, C. H., Zhang, Y. (., Castro, A. F., Feldman, H. I., Kusek, J. W., Eggers, P., Van Lente, F., Greene, T., et al. (2009) · Annals of Internal Medicine · doi:10.7326/0003-4819-150-9-200905050-00006 · Cited by 25,603
The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group (2002) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.288.23.2981 · Cited by 5,664
Normalizing mitochondrial superoxide production blocks three pathways of hyperglycaemic damage
Nishikawa, T., Edelstein, D., Du, X. L., Yamagishi, S.-I., Matsumura, T., Kaneda, Y., Yorek, M. A., Beebe, D., Oates, P. J., Hammes, H.-P., et al. (2000) · Nature · doi:10.1038/35008121 · Cited by 4,277 · cited 1×
“Glycemic fluctuations may generate endothelial dysfunction and ultimately atherosclerosis, triggered by higher circulating levels of inflammatory cytokines and monocyte/macrophage adhesion to endothelial cells, as well as oxidative stress induced by glucose oscillations (16,17,24,25).”
BackgroundPrevalence of and Trends in Diabetes Among Adults in the United States, 1988-2012
Menke, A., Casagrande, S., Geiss, L., & Cowie, C. C. (2015) · JAMA · doi:10.1001/jama.2015.10029 · Cited by 2,362
Esposito, K., Nappo, F., Marfella, R., Giugliano, G., Giugliano, F., Ciotola, M., Quagliaro, L., Ceriello, A., & Giugliano, D. (2002) · Circulation · doi:10.1161/01.cir.0000034509.14906.ae · Cited by 1,961 · cited 2×
“While prior studies have focused on people with diabetes (4,5), there is robust evidence to suggest that the pathophysiological changes associated with glycemic fluctuations compared with stable glucose levels, including higher levels of inflammatory cytokines and the resulting endothelial dysfunction, are manifest in…”
BackgroundU.K. Prospective Diabetes Study Group (1995) · Diabetes · doi:10.2337/diab.44.11.1249 · Cited by 1,923
Mortality and cardiovascular disease in type 1 and type 2 diabetes
Rawshani, A., Rawshani, A., Franzén, S., Eliasson, B., Svensson, A.-M., Miftaraj, M., McGuire, D. K., Sattar, N., Rosengren, A., & Gudbjörnsdottir, S. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1608664 · Cited by 1,389 · cited 1×
“Glycemic impairment, including in the nondiabetic range, is an independent risk factor for cardiovascular disease (CVD) and overall mortality (2,3).”
BackgroundCeriello, A., Esposito, K., Piconi, L., Ihnat, M. A., Thorpe, J. E., Testa, R., Boemi, M., & Giugliano, D. (2008) · Diabetes · doi:10.2337/db08-0063 · Cited by 1,310 · cited 2×
“While prior studies have focused on people with diabetes (4,5), there is robust evidence to suggest that the pathophysiological changes associated with glycemic fluctuations compared with stable glucose levels, including higher levels of inflammatory cytokines and the resulting endothelial dysfunction, are manifest in…”
BackgroundGlycaemic variability in diabetes: clinical and therapeutic implications
Ceriello, A., Monnier, L., & Owens, D. (2019) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(18)30136-0 · Cited by 588 · cited 1×
“Our study expands on the findings from previous studies that have also shown an association of glycemic variability with mortality (4,15) and CVD (4,5,15).”
ResultLong-term Glycemic Variability and Risk of Adverse Outcomes: A Systematic Review and Meta-analysis
Gorst, C., Kwok, C. S., Aslam, S., Buchan, I., Kontopantelis, E., Myint, P. K., Heatlie, G., Loke, Y., Rutter, M. K., & Mamas, M. A. (2015) · Diabetes Care · doi:10.2337/dc15-1188 · Cited by 530
Hirakawa, Y., Arima, H., Zoungas, S., Ninomiya, T., Cooper, M., Hamet, P., Mancia, G., Poulter, N., Harrap, S., Woodward, M., et al. (2014) · Diabetes Care · doi:10.2337/dc14-0199 · Cited by 363 · cited 1×
“and outcomes (CVD or mortality) was only observed in the intensive glucoselowering arm (22,23).”
BackgroundNalysnyk, L., Hernandez‐Medina, M., & Krishnarajah, G. (2010) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2009.01160.x · Cited by 343 · cited 3×
“Our study expands on the findings from previous studies that have also shown an association of glycemic variability with mortality (4,15) and CVD (4,5,15).”
BackgroundMethodResultGlycemic Variation and Cardiovascular Risk in the Veterans Affairs Diabetes Trial
Zhou, J. J., Schwenke, D. C., Bahn, G., & Reaven, P. (2018) · Diabetes Care · doi:10.2337/dc18-0548 · Cited by 131 · cited 1×
“and outcomes (CVD or mortality) was only observed in the intensive glucoselowering arm (22,23).”
BackgroundGlycemic Variability: Both Sides of the Story
Ceriello, A., & Kilpatrick, E. S. (2013) · Diabetes Care · doi:10.2337/dcs13-2030 · Cited by 111
Meugnier, E., Faraj, M., Rome, S., Beauregard, G., Michaut, A., Pelloux, V., Chiasson, J.-L., Laville, M., Clement, K., Vidal, H., et al. (2007) · Diabetes · doi:10.2337/db06-1242 · Cited by 76
Cited by
Glycemic variability: adverse clinical outcomes and how to improve it?
Zhou, Z., Sun, B., Huang, S., Zhu, C., & Bian, M. (2020) · Cardiovascular Diabetology · doi:10.1186/s12933-020-01085-6 · Cited by 255
Glycemic variability and cardiovascular disease in patients with type 2 diabetes
Martinez, M., Santamarina, J., Pavesi, A., Musso, C., & Umpierrez, G. E. (2021) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2020-002032 · Cited by 155
Continuous glucose monitoring for the routine care of type 2 diabetes mellitus
Ajjan, R. A., Battelino, T., Cos, X., Del Prato, S., Philips, J.-C., Meyer, L., Seufert, J., & Seidu, S. (2024) · Nature Reviews Endocrinology · doi:10.1038/s41574-024-00973-1 · Cited by 117
Lee, S., Zhou, J., Wong, W. T., Liu, T., Wu, W. K. K., Wong, I. C. K., Zhang, Q., & Tse, G. (2021) · BMC Endocrine Disorders · doi:10.1186/s12902-021-00751-4 · Cited by 97
Cardiorenal diseases in type 2 diabetes mellitus: clinical trials and real-world practice
Lim, L.-L., Chow, E., & Chan, J. C. N. (2023) · Nature Reviews Endocrinology · doi:10.1038/s41574-022-00776-2 · Cited by 91
Metadata
- Authors
- Echouffo-Tcheugui, J. B., Zhao, S., Brock, G., Matsouaka, R. A., Kline, D., & Joseph, J. J.
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2019-01-18
- Volume
- 42
- Issue
- 3
- Pages
- 486-493
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- OpenAlex
- W2908800459
- Cited by
- 161
- References
- 16
- FWCI
- 15.49
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.